GHRP-2 and hexarelin challenge
In healthy volunteers, both stimulated GH and produced responses involving prolactin and the ACTH-cortisol axis. [1]
Compound evidence dossier · O-007
GHRP-2, GHRP-6, and hexarelin
Three older growth-hormone secretagogues with a shared ghrelin-receptor mechanism. Human studies show hormone responses, not the marketed physique and recovery outcomes.
What does the evidence say?
GHRP-2, GHRP-6 and hexarelin can release growth hormone in humans, but that does not establish muscle gain, recovery, fat loss or anti-ageing benefit. Human challenge studies also show that the compounds are not confined to GH: acute rises in prolactin, ACTH or cortisol have been reported under some conditions. Those short studies do not quantify the harms of repeated non-medical use.
Claim check
Which claims survive an evidence check?
Each row keeps the claim, its best supporting evidence and the limiting caveat together.
All three are selective GH releasersOverstated
They act through the ghrelin receptor and release GH, but human challenge studies also reported prolactin and ACTH-cortisol responses. Selectivity depends on compound, condition and endpoint.
A stronger GH pulse means better recoveryNot demonstrated
Short endocrine studies did not test injury healing, training recovery, muscle gain or durable body-composition benefit. The hormone change cannot stand in for those outcomes.
GHRP-6 is proven to increase useful appetiteOutcome unclear
Ghrelin-receptor agonism can affect appetite, but a pharmacological effect is not evidence of a safe, useful treatment for a consumer goal.
Hexarelin has cardiac benefitsPreclinical and indirect
Some literature discusses cardiovascular mechanisms, yet this does not establish a safe clinical benefit from market products. Direct human outcome trials for promoted use are absent.
Human evidence
What have studies in people shown?
The clearest human evidence comes from short endocrine challenge studies. They help identify hormone responses and off-target signals, while leaving clinical benefit and repeated-use safety unanswered.
Hexarelin study boundary
A chronic short-term study did not find sustained overstimulation of the pituitary-adrenal or prolactin axes. That tempers a blanket claim, but it does not create long-term safety evidence. [2]
Hormones changed; sleep did not improve
A small healthy-volunteer study found hormone increases and reduced slow-wave sleep under its conditions, opposing a simple sleep-benefit narrative. [3]
Critical distinction
Shared mechanism, different evidence limits
Grouping the compounds is useful for the receptor pathway and sport rule. It should not erase differences in potency, study design or adverse-effect evidence.
- Shared pathway
- GHRP-2, GHRP-6 and hexarelin act as ghrelin-receptor agonists and GH secretagogues.
- Human evidence type
- Mostly short hormone-challenge studies, often in small groups of healthy volunteers.
- Off-target finding
- Prolactin and ACTH-cortisol responses have appeared under some acute conditions. They should not be stated as inevitable chronic harm.
- Missing comparison
- No dependable head-to-head outcome programme shows which product provides a meaningful consumer benefit with less harm.
Risk register
What could go wrong?
Endocrine effects are biologically active, and the market-product layer adds uncertainties that short research studies were not designed to measure.
| Risk channel | Evidence-aware interpretation |
|---|---|
| Acute endocrine signals | Changes in prolactin, ACTH and cortisol have been observed under some study conditions. Clinical significance with repeated use is uncertain. |
| Metabolic concern | The FDA flags potential cortisol effects and increased blood glucose through reduced insulin sensitivity for compounded GHRP-6. |
| Product risk | Aggregation, peptide-related impurities, incorrect strength and non-sterility are separate from the pharmacology of a verified research material. |
| Unknowns | Long-term endocrine adaptation, cardiovascular outcomes, interactions and risk in vulnerable populations are not adequately defined. |
Product evidence
What would evidence about a vial prove?
A compound-level literature verdict and a product-level finding answer different questions. Neither can substitute for the other.
Claimed compound
The literature applies only if the vial contains the same active substance and form that the source studied.
Label and release record
A batch-specific record should identify the material, method, result, specification and accountable laboratory.
Submitted sample
A defensible result concerns the sample tested. It does not certify every vial, future batch or storage condition.
Clinical meaning
Identity, purity and sterility evidence cannot establish a health outcome or fill a missing human safety dataset.
Status check
Is it authorised or prohibited?
Medicine authorisation, lawful supply and anti-doping status are separate checks. Each can change and should be verified at the point of decision.
| System | Finding checked 8 August 2026 |
|---|---|
| UK medicine status | No current UK-authorised medicines containing GHRP-2, GHRP-6 or hexarelin were identified in the MHRA database check. |
| United States | These compounds are not FDA-approved medicines for the physique, recovery or wellness uses promoted online. The FDA has flagged safety and product-quality concerns for compounded GHRP-6. |
| Sport | The 2026 WADA list names GHRP-2, GHRP-6 and examorelin (hexarelin) among prohibited growth-hormone-releasing peptides. They are prohibited at all times. |
Method note
How was this judgement made?
We used human challenge studies for hormone effects, retained the chronic-study qualification, and did not convert endocrine signals into clinical outcomes or guaranteed harms.
Searches prioritised regulator documents, current medicine and anti-doping records, trial registrations and indexed primary studies. Seller pages were not used as evidence of efficacy or safety.
Read the full editorial method and inspect the evidence library.
Source ledger
Primary sources
- Arvat et al., GHRP-2 and hexarelin endocrine responses in humansHealthy-volunteer endocrine challenge study. Checked 8 August 2026.
- Rahim et al., repeated hexarelin administrationShort human study that qualifies claims about sustained off-target stimulation. Checked 8 August 2026.
- Frieboes et al., GHRP-2 effects on sleep and hormonesSmall healthy-volunteer study; hormone and sleep endpoints. Checked 8 August 2026.
- US FDA, Certain Bulk Drug Substances That May Present Significant Safety RisksCurrent regulator summary of characterisation, impurity, immunogenicity and safety concerns. Checked 8 August 2026.
- World Anti-Doping Agency, 2026 Prohibited ListCurrent list used for sport-status checks; effective 1 January 2026. Checked 8 August 2026.
- MHRA ProductsPublic UK medicines database used for the marketing-authorisation check. Checked 8 August 2026.
Questions answered
Frequently asked questions
Short answers keep the decisive caveat beside the claim.
What do GHRP-2, GHRP-6 and hexarelin have in common?
They are ghrelin-receptor agonists that can trigger growth-hormone release. Their shared pathway supports grouping them for a mechanism review, but does not make their potency or full risk profiles identical.
Do they raise cortisol or prolactin?
Acute human challenge studies reported prolactin and ACTH-cortisol responses under some conditions. A short repeated-hexarelin study did not show sustained overstimulation. The long-term clinical meaning remains uncertain.
Are they proven to build muscle?
No reliable human outcome trials establish muscle gain from GHRP-2, GHRP-6 or hexarelin. Short hormone studies do not measure the advertised physique result.
Is hexarelin the same as examorelin?
Yes. Examorelin is another name used for hexarelin. Name matching helps with literature and anti-doping checks, but a label still does not prove a vial’s identity.
Are these compounds prohibited in sport?
Yes. The 2026 WADA list names GHRP-2, GHRP-6 and examorelin (hexarelin) within the prohibited peptide-hormone class. The prohibition applies at all times.
Can one study settle the safety of the whole group?
No. Study duration, compound, route, population and endpoint matter. Shared mechanism supports caution across the group, while compound-specific risks still need direct evidence.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-007, GHRP-2, GHRP-6, and hexarelin was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 10 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.